Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer

Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]) has appointed David Lebwohl to serve as executive vice president and chief medical officer. He is joining the Cambridge, MA-based gene-editing therapies company from Semma Therapeutics, where he also held the chief medical officer position. Lebwohl’s prior experience includes positions at Novartis (NYSE: [[ticker:NVS]]) and Bristol Myers Squibb (NYSE: [[ticker:BMY]]).

Intellia is developing therapies edited with the CRISPR technology. It has in vivo therapies in preclinical development under a partnership with Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]) and ex vivo therapies in preclinical development via an alliance with Novartis.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan